CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 102 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,839,357 | +27.7% | 123,364 | -6.2% | 0.00% | 0.0% |
Q2 2023 | $1,440,692 | +39.0% | 131,570 | +10.7% | 0.00% | 0.0% |
Q1 2023 | $1,036,189 | +42.2% | 118,829 | +2.3% | 0.00% | 0.0% |
Q4 2022 | $728,656 | +117.5% | 116,213 | +21.6% | 0.00% | – |
Q3 2022 | $335,000 | +121.9% | 95,594 | +87.3% | 0.00% | – |
Q2 2022 | $151,000 | -2.6% | 51,027 | +2.3% | 0.00% | – |
Q1 2022 | $155,000 | -16.2% | 49,872 | -9.1% | 0.00% | – |
Q4 2021 | $185,000 | +50.4% | 54,863 | +62.8% | 0.00% | – |
Q3 2021 | $123,000 | -42.0% | 33,698 | -30.8% | 0.00% | – |
Q2 2021 | $212,000 | +38.6% | 48,698 | +44.8% | 0.00% | – |
Q1 2021 | $153,000 | +37.8% | 33,633 | +74.4% | 0.00% | – |
Q4 2020 | $111,000 | -20.7% | 19,283 | -0.4% | 0.00% | – |
Q3 2020 | $140,000 | +278.4% | 19,359 | +82.2% | 0.00% | – |
Q2 2020 | $37,000 | -52.6% | 10,625 | -30.3% | 0.00% | – |
Q3 2019 | $78,000 | -27.1% | 15,239 | +2.2% | 0.00% | – |
Q2 2019 | $107,000 | -47.0% | 14,915 | -2.1% | 0.00% | – |
Q1 2019 | $202,000 | +4.7% | 15,238 | -37.9% | 0.00% | -100.0% |
Q4 2018 | $193,000 | -31.6% | 24,528 | -3.5% | 0.00% | 0.0% |
Q3 2018 | $282,000 | +116.9% | 25,422 | +154.2% | 0.00% | – |
Q1 2018 | $130,000 | – | 10,000 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |